#United States #Atlanta #financial results #Artivion #Aortic Disease

Artivion Reports Strong Financial Performance in Q2 2025

Artivion, Inc., a renowned leader in cardiac and vascular surgical solutions, recently announced its financial results for the second quarter of 2025, marking a pivotal moment in the company’s trajectory. The report highlighted a robust revenue growth of 15%, equivalent to $113.0 million, compared to the same quarter last year. This also reflects a 14% increase on a non-GAAP constant currency basis, underscoring the company’s operational strength in a competitive market.

Key Highlights

One of the standout features of this quarter was the significant growth in product sales. The On-X mechanical heart valves and stent grafts both surged by over 20% on a constant currency basis. Specifically, On-X saw a remarkable 24% growth compared to Q2 2024. Other contributing products, such as BioGlue and Preservation Services, also reported incremental growth.

The net income reached $1.3 million or $0.03 per fully diluted share, improving on the previous year's loss of $2.1 million. In addition to this positive shift, the adjusted EBITDA displayed an impressive increase of 33%, amounting to $24.8 million, signifying efficient cost management and enhanced profitability.

Strategic Milestones

Beyond financial metrics, Artivion achieved a significant regulatory milestone by receiving Investigational Device Exemption (IDE) approval from the U.S. FDA. This approval allows the company to commence the ARTIZEN pivotal trial, focusing on the efficacy and safety of the Arcevo LSA device, which aims to improve treatment options for acute and chronic aortic arch diseases. This advancement not only illustrates the company’s commitment to innovation but also reinforces its position as a leader in aortic disease treatment.

Stronger Capital Structure

The financial report also indicated a significant improvement in Artivion's capital structure. The company exchanged $99.5 million in outstanding convertible senior notes for common stock, effectively retiring a substantial amount of its debt and aiming for a more streamlined financial position moving forward. Pat Mackin, Chairman and CEO, expressed confidence in the company's strategy, highlighting that their robust performance and innovative pipeline position them favorably for future growth.

Outlook for 2025

Looking ahead, Artivion is optimistic about its 2025 prospects. The company has raised its revenue guidance midpoint, now anticipating a constant currency growth ranging from 12% to 14%. This adjustment reflects a strong belief in ongoing business momentum, driven by the strong results of Q2. The forecast also anticipates an adjusted EBITDA growth between 21% to 28% for the full year.

In summary, Artivion's second quarter financial results not only demonstrate solid growth across product lines but also highlight the company's dedication to innovation and improvement. With a clear focus on aortic disease solutions and a strong capital foundation, Artivion is well-positioned to meet the challenges in the healthcare sector while delivering value to its stakeholders.

About Artivion, Inc.

Based in Atlanta, Georgia, Artivion, Inc. specializes in developing unique solutions for cardiac and vascular surgical procedures. With a comprehensive product portfolio, the company serves more than 100 countries, ensuring that healthcare providers are equipped with the best tools to treat aortic diseases effectively.

For more information about Artivion's innovative offerings, visit their website at www.Artivion.com.